Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study?
Lopez-Liuchi
J V
JV
Département de Médecine Interne, Hôpital Universitaire de Genève, Geneva, Switzerland.
Meier
C A
CA
D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004035:Diet Therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D010629:Phenformin / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D014044:Tolbutamide / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D014044:Tolbutamide; D010629:Phenformin